Strategic Review of Jerini Assets Completed
Jerini AG and Shire Deutschland Investments GmbH have completed the strategic review of the assets and programs of Jerini AG, not related to Icatibant (Firazyr®), as referred to in the Offer Document published by Shire Deutschland Investments GmbH on August 13, 2008. The Jerini Supervisory Board and Management Board concluded now that it is in the best interests of Jerini AG to divest Jerini Ophthalmic, Inc, JPT Peptide Technologies GmbH (JPT), and Jerini's pre-clinical projects. Jerini AG will now explore options to maximize benefits for Jerini AG from the divestment of these assets.
Most read news
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Magnetic nanoparticles navigate therapeutic genes through the body - PTB measures the pinpointed transport of therapeutics for cardiovascular diseases
QIAGEN and British Veterinary Laboratories Agency Expand Partnership in Veterinary Testing - New agreement covers widespread bacterial infections in horses
Medical Technology - A Safe Haven for Volatile Industries
Pharmexa presents data from influenza program
Dental_public_health
